The Board of Directors at its Meeting held today have approved Audited Financial Results of the Company for quarter and financial year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.0 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Prevest Denpro Limited has reported audited financial results for FY26 with standalone revenue from operations of ₹7,166.42 Lakhs, up 13.6% from ₹6,306.77 Lakhs in FY25. The company achieved a standalone net profit of ₹2,141.82 Lakhs, representing a 17.7% increase over the previous year's ₹1,820.13 Lakhs. Consolidated figures show revenue of ₹7,180.85 Lakhs and net profit of ₹2,049.05 Lakhs, up 13.9% and 12.9% respectively. EPS grew from ₹15.16 to ₹17.84 on standalone basis. The company maintains a strong cash position with cash and cash equivalents of ₹7,264.97 Lakhs. The statutory auditor Mittal & Associates issued an unmodified opinion, confirming clean audit findings with no qualifications.
The company delivered solid double-digit growth in both revenue and profit, though growth rates fell short of the 20%+ revenue growth and 25%+ PAT growth thresholds. The clean audit with unmodified opinion provides additional confidence in financial reporting quality.